New therapy for lung cancer!
Apparatus
-
-
The global ADC drug market will be approximately $5.2 billion by 2021
-
HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.
-
Apparatus
Significantly Longer Survival In Refractory Breast Cancer With The Addition Of Eganelisib To Standard Treatment!
Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.
-
The Fraunhofer Institute in Germany has now developed two techniques that could make testing faster and cheaper.
-
Apparatus
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
Recently, a study for the treatment of advanced EGFR-mutated and c-MET-positive lung cancer showed good results with the cutting-edge ADC drug teliso-V in combination with the EGFR generation-targeted drug troche (i.e. erlotinib).
-
Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."
-
The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.
-
Apparatus
The Frontier Drug INT230-6 Has Shown Promising Therapeutic Results In Soft Tissue Sarcoma!
Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.
-
SKB264 is currently in Phase II and Phase III clinical trials as a single agent/combination for multiple tumour types.